Bristol-Myers Opdivo Cancer Drug Meets Endpoint

Bristol-Myers Squibb said that a late-stage study of its advanced skin-cancer drug Opdivo met its primary endpoint and the company would end the trial early.



from WSJ.com: US Business http://ift.tt/1IjID2p

via IFTTT